A novel rhabdovirus-based anthrax vaccine

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$1,067,665.00
Award Year:
2006
Program:
STTR
Phase:
Phase I
Contract:
1R41AI063822-01A2
Award Id:
80431
Agency Tracking Number:
AI063822
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
882 SOUTH MATLACK STREET, SUITE 105, WEST CHESTER, PA, 19382
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
MATTHIASSCHNELL
(215) 503-4634
matthias.schnell@jefferson.edu
Business Contact:
KOONPAK
(610) 738-7938
cpak@mtarget.com
Research Institute:
THOMAS JEFFERSON UNIVERSITY

THOMAS JEFFERSON UNIVERSITY
201 SOUTH 11TH ST
PHILADELPHIA, PA, 19107

Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): Bioterrorism using anthrax is a major risk in the US and abroad, and, therefore, has been classified as an NIAID Category A Priority Pathogen. The best strategy against anthrax is a safe and effective vaccine. The existing human vaccine against Anthrax has a history of a high incidence of toxicity and modest, transient humoral immune responses. This project proposes the development of a potent Anthrax vaccine by using a viral capsid protein as a carrier for the anthrax protective antigen (PA). Studies have shown that foreign antigens presented to the immune system as fusion proteins with recombinant rabies virus (RV) ribonucleoprotein (RNP), induce more potent humoral responses than when presented as the protein antigens alone. This proposal is based on the overall hypothesis that presentation of anthrax (PA) to the immune system in the highly organized and repetitive manner, as expected for a nucleoprotein fusion protein (Nfu) in RNP, should be superior to the use of monomeric recombinant anthrax PA. The aims of this project are: Aim 1: Test the safety and immunogenicity of recombinant Nfu-PA-RNPs in mice. The existing vaccine, recombinant PA, and E. coli-produced Nfu-PA (monomeric) will serve as controls. Aim 2: Assess the ability of sera from Nfu-PA-RNP immunized mice to neutralize toxin in vitro, and to assess the efficacy of the Nfu-PA-RNP vaccine in a mouse Anthrax toxin challenge model and an aerosol Anthrax challenge model. Aim 3: Demonstrate feasibility of a purification process for the Nfu-PA-RNPs that consists of conventional scalable methods for potential commercial production. This research is directly relevant to public health in that it is directed towards development of a more effective, less toxic vaccine for a pathogen classified as having the highest threat to national security. The general concept, if proven successful, may also lead to a general technique for developing more effective vaccines for other important pathogens.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government